Working... Menu
Trial record 1 of 4 for:    "Systemic Lupus Erythematosus" | "Atorvastatin"
Previous Study | Return to List | Next Study

An Open Labeled Pilot Study of Atorvastatin in Systemic Lupus Erythematosus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00432354
Recruitment Status : Unknown
Verified March 2007 by Buddhist Tzu Chi General Hospital.
Recruitment status was:  Recruiting
First Posted : February 7, 2007
Last Update Posted : March 20, 2007
Information provided by:
Buddhist Tzu Chi General Hospital

Brief Summary:
The aim of this study is to to determine whether atorvastatin 40mg per day is effective in the treatment of SLE.

Condition or disease Intervention/treatment Phase
Systemic Lupus Erythematosus Drug: atorvastatin Phase 2 Phase 3

Detailed Description:

Background: Statins are lipid-lower agents with pleiotropic effects. Beyond the traditional effect as inhibitors of 3-hydroxy-3methylglytaryl coenzyme A (HMG-CoA) reductase, it has anti-inflammatory and immunomodulatory properties. The administration of atorvastatin to lupus-prone model NZB/W F1 mice results in a significant reduction in serum IgG anti-dsDNA Abs and decreased proteinuria. In a pilot study with three patients with SLE, simvastatin induced rapid and significant reduction in proteinuria levels. However, further randomized double-blinded placebo-controlled study is pending.

Objective: The goal of this study was to evaluate the clinical efficacy and laboratory effect of atorvastatin in SLE.

Methods: Forty patients with SLE will randomize in two groups to receive atorvastatin or not as an adjuvant to immunosuppressive agent therapy. Patients who received atorvastatin for 6 months will stop atorvastatin for 8 weeks as a washout period. We will cross over the placebo and experimental groups, then given atorvastatin for another 6 months. Primary outcome is improvement of lupus disease status measured by SLEDAI and microcirculation improvement via nailfold capillaroscopy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : March 2007
Estimated Study Completion Date : March 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lupus

Primary Outcome Measures :
  1. The primary outcome was the change in SLE-DAI, a validated composite disease activity score.

Secondary Outcome Measures :
  1. The secondary endpoint was the improvement of microcirculation evaluated by Raynaud’s condition score and nailfold capillaroscopy in the beginning and end of the atorvastatin.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   16 Years to 80 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. 16–80 years of age, fulfilling ACR criteria for the classification of SLE (no limit on disease duration)
  2. Active disease status including (1) active nephritis with moderate proteinuria (between 1.0gm/day and 2.5gm/day) despite ongoing immunosuppressive therapy or (2) moderate active extra-renal component of the SLEDAI score in the range of 3 to 10. The SLE-DAI score should have been stable for at least two weeks prior to screening.
  3. The type and number immunosuppressive agents were not changed in recent one months

Exclusion Criteria:

  1. inability to give informed consent;
  2. myositis (CK>3×normal value);
  3. dialysis or serum creatinin>2.5mg/dL;
  4. abnormal liver function (ALT>3×normal value);
  5. pregnant or breastfeeding;
  6. life-threatening illness that would interfere with ability to complete the study;
  7. current drug or alcohol abuse
  8. Already under statin therapy
  9. Active SLE disease need added new immunosuppressive agent or increased current drug dosage for more than 50%.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00432354

Layout table for location contacts
Contact: Ming-Chi Lu, MD 886-5-2648000 ext 5201

Layout table for location information
Buddhist Dalin Tzu Chi General Hospital Not yet recruiting
Chia-Yi, Taiwan, 622
Contact: Ming-Chi Lu, MD    886-5-2648000 ext 5201   
Principal Investigator: Ming-Chi Lu, MD         
Dalin Tzu Chi General Hospital Recruiting
Chia-yi, Taiwan, 622
Contact: Ming-Chi Lu, MD    05-2648000 ext 5201   
Contact: Ning-Sheng Lai, MD, Phd    05-2648000 ext 5006      
Sponsors and Collaborators
Buddhist Tzu Chi General Hospital
Layout table for investigator information
Study Chair: Ning-Sheng Lai, MD., Ph.D. Vice President of Buddhist Dalin Chi Tzu General Hospital

Publications of Results:
Other Publications:
Layout table for additonal information Identifier: NCT00432354     History of Changes
Other Study ID Numbers: DTCRD 96-03
First Posted: February 7, 2007    Key Record Dates
Last Update Posted: March 20, 2007
Last Verified: March 2007

Keywords provided by Buddhist Tzu Chi General Hospital:
systemic lupus erythematosus

Additional relevant MeSH terms:
Layout table for MeSH terms
Lupus Erythematosus, Systemic
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors